218 related articles for article (PubMed ID: 10220571)
1. ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P.
Chen ZS; Furukawa T; Sumizawa T; Ono K; Ueda K; Seto K; Akiyama SI
Mol Pharmacol; 1999 May; 55(5):921-8. PubMed ID: 10220571
[TBL] [Abstract][Full Text] [Related]
2. Reversal of MRP-mediated vincristine resistance in KB cells by buthionine sulfoximine in combination with PAK-104P.
Chuman Y; Chen ZS; Seto K; Sumizawa T; Furukawa T; Tani A; Haraguchi M; Niwa K; Yamada K; Aikou T; Akiyama S
Cancer Lett; 1998 Jul; 129(1):69-76. PubMed ID: 9714337
[TBL] [Abstract][Full Text] [Related]
3. Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P.
Sumizawa T; Chen ZS; Chuman Y; Seto K; Furukawa T; Haraguchi M; Tani A; Shudo N; Akiyama SI
Mol Pharmacol; 1997 Mar; 51(3):399-405. PubMed ID: 9058594
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P.
Marbeuf-Gueye C; Salerno M; Quidu P; Garnier-Suillerot A
Eur J Pharmacol; 2000 Mar; 391(3):207-16. PubMed ID: 10729360
[TBL] [Abstract][Full Text] [Related]
5. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter.
Chen ZS; Kawabe T; Ono M; Aoki S; Sumizawa T; Furukawa T; Uchiumi T; Wada M; Kuwano M; Akiyama SI
Mol Pharmacol; 1999 Dec; 56(6):1219-28. PubMed ID: 10570049
[TBL] [Abstract][Full Text] [Related]
6. Reversal of heavy metal resistance in multidrug-resistant human KB carcinoma cells.
Chen ZS; Mutoh M; Sumizawa T; Furukawa T; Haraguchi M; Tani A; Akiyama S
Biochem Biophys Res Commun; 1997 Jul; 236(3):586-90. PubMed ID: 9245693
[TBL] [Abstract][Full Text] [Related]
7. PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein.
Vanhoefer U; Cao S; Minderman H; Tóth K; Scheper RJ; Slovak ML; Rustum YM
Clin Cancer Res; 1996 Feb; 2(2):369-77. PubMed ID: 9816180
[TBL] [Abstract][Full Text] [Related]
8. An enhanced active efflux of CPT-11 and SN-38 in cisplatin-resistant human KB carcinoma cells.
Chen ZS; Sumizawa T; Furukawa T; Ono K; Tani A; Komatsu M; Akiyama S
Cancer Lett; 1999 Apr; 138(1-2):13-22. PubMed ID: 10378768
[TBL] [Abstract][Full Text] [Related]
9. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines.
Chu XY; Suzuki H; Ueda K; Kato Y; Akiyama S; Sugiyama Y
J Pharmacol Exp Ther; 1999 Feb; 288(2):735-41. PubMed ID: 9918583
[TBL] [Abstract][Full Text] [Related]
10. Two pyridine analogues with more effective ability to reverse multidrug resistance and with lower calcium channel blocking activity than their dihydropyridine counterparts.
Shudo N; Mizoguchi T; Kiyosue T; Arita M; Yoshimura A; Seto K; Sakoda R; Akiyama S
Cancer Res; 1990 May; 50(10):3055-61. PubMed ID: 1970752
[TBL] [Abstract][Full Text] [Related]
11. An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells.
Chen ZS; Mutoh M; Sumizawa T; Furukawa T; Haraguchi M; Tani A; Saijo N; Kondo T; Akiyama S
Exp Cell Res; 1998 May; 240(2):312-20. PubMed ID: 9597004
[TBL] [Abstract][Full Text] [Related]
12. Human multidrug resistance associated protein 4 confers resistance to camptothecins.
Tian Q; Zhang J; Tan TM; Chan E; Duan W; Chan SY; Boelsterli UA; Ho PC; Yang H; Bian JS; Huang M; Zhu YZ; Xiong W; Li X; Zhou S
Pharm Res; 2005 Nov; 22(11):1837-53. PubMed ID: 16132345
[TBL] [Abstract][Full Text] [Related]
13. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein.
Jansen WJ; Hulscher TM; van Ark-Otte J; Giaccone G; Pinedo HM; Boven E
Br J Cancer; 1998; 77(3):359-65. PubMed ID: 9472629
[TBL] [Abstract][Full Text] [Related]
14. [Mechanisms for resistance to anticancer agents and the reversal of the resistance].
Akiyama S; Chen ZS; Kitazono M; Sumizawa T; Furukawa T; Aikou T
Hum Cell; 1999 Sep; 12(3):95-102. PubMed ID: 10695015
[TBL] [Abstract][Full Text] [Related]
15. Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells.
Kitazono M; Okumura H; Ikeda R; Sumizawa T; Furukawa T; Nagayama S; Seto K; Aikou T; Akiyama S
Int J Cancer; 2001 Jan; 91(1):126-31. PubMed ID: 11149411
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of glutathione and daunorubicin efflux from multidrug resistance protein overexpressing small-cell lung cancer cells.
Salerno M; Garnier-Suillerot A
Eur J Pharmacol; 2001 Jun; 421(1):1-9. PubMed ID: 11408043
[TBL] [Abstract][Full Text] [Related]
17. MRP1 modulation by PAK-104P: detection with technetium-99m-MIBI in cultured lung tumor cells.
Vergote J; Moretti JL; Kouyoumdjian JC; Garnier-Suillerot A
Anticancer Res; 2002; 22(1A):251-6. PubMed ID: 12017298
[TBL] [Abstract][Full Text] [Related]
18. Non-P-glycoprotein-mediated multidrug-resistant human KB cells selected in medium containing adriamycin, cepharanthine, and mezerein.
Sumizawa T; Chuman Y; Sakamoto H; Iemura K; Almquist KC; Deeley RG; Cole SP; Akiyama S
Somat Cell Mol Genet; 1994 Sep; 20(5):423-35. PubMed ID: 7825064
[TBL] [Abstract][Full Text] [Related]
19. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP).
Vanhoefer U; Cao S; Harstrick A; Seeber S; Rustum YM
Ann Oncol; 1997 Dec; 8(12):1221-8. PubMed ID: 9496387
[TBL] [Abstract][Full Text] [Related]
20. Decreased drug accumulation without increased drug efflux in a novel MRP-overexpressing multidrug-resistant cell line.
Gaj CL; Anyanwutaku I; Chang YH; Cheng YC
Biochem Pharmacol; 1998 Apr; 55(8):1199-211. PubMed ID: 9719474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
